$Billions invested here instead of abroad tariffs working as intended.
Eli Lilly on Tuesday announced a $5 billion investment in a manufacturing facility in Virginia as the pharmaceutical giant looks to expand its domestic production capacity amid the threat of tariffs.
The manufacturing facility is expected to generate 650 high-wage jobs and 1,800 construction jobs at the West Creek Business Park in Goochland County, Virginia. The facility will produce active pharmaceutical ingredients for cancer, autoimmune and other advanced therapies.
Eli Lilly's announcement represents an expansion beyond the original plan for a $2.1 billion facility that would've created 468 jobs.
"Our investment in Virginia underscores our commitment to U.S. innovation and manufacturing – creating high-quality jobs, strengthening communities, and advancing the health and well-being of Americans nationwide," said Lilly CEO David Ricks. "By expanding our domestic capacity, we're building a secure, resilient supply chain that delivers for patients today and supports the breakthrough medicines of tomorrow."
Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats
Eli Lilly on Tuesday announced a $5 billion investment in a manufacturing facility in Virginia as the pharmaceutical giant looks to expand its domestic production capacity amid the threat of tariffs.
The manufacturing facility is expected to generate 650 high-wage jobs and 1,800 construction jobs at the West Creek Business Park in Goochland County, Virginia. The facility will produce active pharmaceutical ingredients for cancer, autoimmune and other advanced therapies.
Eli Lilly's announcement represents an expansion beyond the original plan for a $2.1 billion facility that would've created 468 jobs.
"Our investment in Virginia underscores our commitment to U.S. innovation and manufacturing – creating high-quality jobs, strengthening communities, and advancing the health and well-being of Americans nationwide," said Lilly CEO David Ricks. "By expanding our domestic capacity, we're building a secure, resilient supply chain that delivers for patients today and supports the breakthrough medicines of tomorrow."